

Elisabetta Abruzzese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/109424/publications.pdf>

Version: 2024-02-01

233
papers

7,741
citations

81434

41
h-index

68831

81
g-index

237
all docs

237
docs citations

237
times ranked

6324
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	1.2	20
2	Obituary of Prof. Michele Bacarani. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2022, 14, e2022015.	0.5	0
3	Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Frontiers in Oncology</i> , 2022, 12, 835563.	1.3	6
4	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study. <i>British Journal of Haematology</i> , 2022, 197, 190-200.	1.2	7
5	Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	1
6	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. <i>Frontiers in Oncology</i> , 2022, 12, 839915.	1.3	10
7	Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1801.	1.0	10
8	Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. <i>Cancer</i> , 2022, 128, 2449-2454.	2.0	7
9	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678.	0.6	10
10	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	1.2	19
11	Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 192, e139-e144.	1.2	3
12	Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 271-279.	1.2	4
13	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	2.8	41
14	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTIKIMA study. <i>Cancer Medicine</i> , 2021, 10, 1726-1737.	1.3	9
15	Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 631570.	1.3	5
16	Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine kinase inhibitors. <i>Hematological Oncology</i> , 2021, 39, 401-408.	0.8	8
17	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	2.0	14
18	Case Report: Very Late, Atypical Extra-Medullary Relapse in a Patient With Acute Promyelocytic Leukemia (APL) Rescued With a Transplant-Free Approach. <i>Frontiers in Oncology</i> , 2021, 11, 699886.	1.3	0

#	ARTICLE	IF	CITATIONS
19	CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin. <i>Cancers</i> , 2021, 13, 3214.	1.7	20
20	The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population. <i>Cancer Medicine</i> , 2021, 10, 6310-6316.	1.3	13
21	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. <i>Frontiers in Oncology</i> , 2021, 11, 739171.	1.3	6
22	CML-182: SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S329-S330.	0.2	0
23	Chronic Myeloid Leukemia and Pregnancy: Per Aspera Ad Astra. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S153-S155.	0.2	1
24	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta Oncologica</i> , 2021, 60, 1527-1533.	0.8	2
25	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. <i>Blood Advances</i> , 2021, 5, 4504-4514.	2.5	14
26	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021, 100, 2005-2014.	0.8	14
27	Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial. <i>Blood</i> , 2021, 138, 3603-3603.	0.6	6
28	Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial. <i>Blood</i> , 2021, 138, 1475-1475.	0.6	5
29	Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials. <i>Blood</i> , 2021, 138, 2550-2550.	0.6	8
30	Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 3617-3617.	0.6	1
31	Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results. <i>Blood</i> , 2021, 138, 1476-1476.	0.6	1
32	First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib. <i>Blood</i> , 2021, 138, 1474-1474.	0.6	5
33	Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis. <i>Blood</i> , 2021, 138, 3624-3624.	0.6	0
34	Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Blood</i> , 2021, 138, 1479-1479.	0.6	1
35	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020, 301, 163-166.	0.8	21
36	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. <i>Leukemia</i> , 2020, 34, 488-498.	3.3	35

#	ARTICLE	IF	CITATIONS
37	Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network. <i>European Journal of Cancer Care</i> , 2020, 29, e13174.	0.7	3
38	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	2.0	106
39	ALK-negative anaplastic large cell lymphoma with "Hodgkin-like" cytomorphology and nuclear expression of PAX5. <i>Pathology Research and Practice</i> , 2020, 216, 152724.	1.0	2
40	Treatment-Free Remission in Chronic Myeloid Leukemia: Lights and Shadows. <i>Hematology Reports</i> , 2020, 12, 8950.	0.3	7
41	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3692.	1.0	2
42	Impact of SARS CoV-2 in hemoglobinopathies: a protective mechanism being from Beta chain Hemoglobin defects?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020052.	0.5	12
43	Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. <i>Hematological Oncology</i> , 2020, 38, 607-610.	0.8	1
44	Pregnancy outcomes in patients treated with bosutinib. <i>International Journal of Hematologic Oncology</i> , 2020, 9, IJH26.	0.7	17
45	Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms. <i>Expert Review of Hematology</i> , 2020, 13, 1349-1359.	1.0	2
46	CML-206: ReSETting SETD2/H3K36Me3 Deficiency as a New Therapeutic Strategy in Blast Crisis Chronic Myeloid Leukemia Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S236-S237.	0.2	0
47	Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096612.	1.1	29
48	NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020083.	0.5	6
49	SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020031.	0.5	30
50	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020, 99, 1525-1530.	0.8	9
51	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020, 10, 66.	2.8	6
52	Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs. <i>American Journal of Hematology</i> , 2020, 95, E260-E263.	2.0	15
53	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020, 34, 2260-2261.	3.3	57
54	Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. <i>Blood</i> , 2020, 136, 2237-2240.	0.6	13

#	ARTICLE	IF	CITATIONS
55	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	0.8	15
56	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020, 135, 534-541.	0.6	61
57	Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic. <i>Blood</i> , 2020, 136, 43-44.	0.6	11
58	Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE) <i>Tj ETQq0 0 0 rgBt, Overlook 10 Tf 50</i>		
59	Multidimensional Vascular Evaluation in Patients Treated with Tyrosine Kinase Inhibitors (TKIs): From Plaque Formation to Evolution and Follow up on 150 Patients. <i>Blood</i> , 2020, 136, 54-54.	0.6	1
60	Prognostic Significance of Transcript-Type BCR-ABL1 in Chronic Myeloid Leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020062.	0.5	11
61	Sustained Transfusion Independence in Chronic Bone Marrow BM Failure under Long-Term Self-Administration of Moringa Oleifera. <i>Saudi Journal of Medicine</i> , 2020, 05, 50-52.	0.0	0
62	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
63	IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
64	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. <i>Blood</i> , 2020, 136, 45-46.	0.6	1
65	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
66	Impact on Mental Health, Disease Management and Socioeconomic Modifications in Hematological Patients during COVID-19 Pandemia in Italy. <i>Blood</i> , 2020, 136, 35-37.	0.6	4
67	New Perspectives and Challenges Regarding Fertility, Conception and Pregnancy in Hemoglobinopathies. a Multidisciplinary Report of 66 Outcomes. <i>Blood</i> , 2020, 136, 22-23.	0.6	0
68	Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. <i>Haematologica</i> , 2019, 104, 93-101.	1.7	62
69	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019, 98, 2329-2338.	0.8	17
70	TREATMENT PATTERNS IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA IN ROUTINE CLINICAL PRACTICE: THE SIMPLICITY ITALIAN POPULATION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019025.	0.5	7
71	The neutrophil/lymphocyte ratio ≥ 3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network "Rete Ematologica del Lazio per i Linfomi" (RELLI). <i>Leukemia and Lymphoma</i> , 2019, 60, 3386-3394.	0.6	11
72	Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy. <i>Annals of Hematology</i> , 2019, 98, 2609-2611.	0.8	13

#	ARTICLE	IF	CITATIONS
73	Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. Is dPCR the key?. <i>European Journal of Haematology</i> , 2019, 103, 272-273.	1.1	24
74	Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 3330-3332.	0.6	5
75	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019, 98, 1885-1890.	0.8	10
76	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019, 288, 124-127.	0.8	19
77	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	0.8	3
78	Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy. <i>Acta Oncologica</i> , 2019, 58, 888-890.	0.8	2
79	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019, 37, 296-302.	0.8	53
80	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596.	1.7	58
81	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , 2019, 8, 2041-2055.	1.3	63
82	Flow Cytometry Assessment of CD26 + Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 294-299.	0.7	28
83	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	2.5	66
84	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. <i>Journal of Hematology and Oncology</i> , 2019, 12, 131.	6.9	45
85	Back to the future: Treatment-free remission and pregnancy in chronic myeloid leukemia. <i>European Journal of Haematology</i> , 2019, 102, 197-199.	1.1	15
86	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	0.8	10
87	Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation. <i>Blood</i> , 2019, 134, 2919-2919.	0.6	2
88	Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database. <i>Blood</i> , 2019, 134, 498-498.	0.6	11
89	Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party. <i>Blood</i> , 2019, 134, 2931-2931.	0.6	2
90	Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial. <i>Blood</i> , 2019, 134, 1652-1652.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019, 134, 839-839.	0.6	2
92	Mantle CELL Lymphoma (MCL) in Elderly Patients (PTs): The Experience in Real-Life of Rete Ematologica Laziale Linfomi (RELLI). <i>Blood</i> , 2019, 134, 5257-5257.	0.6	0
93	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Blood</i> , 2019, 134, 4153-4153.	0.6	0
94	Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study. <i>Blood</i> , 2019, 134, 2936-2936.	0.6	0
95	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way. <i>Blood</i> , 2019, 134, 4142-4142.	0.6	0
96	Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicineâ€”Results from the Italian â€”Back to Lifeâ€” project. <i>Quality of Life Research</i> , 2018, 27, 1545-1554.	1.5	9
97	Sexual health in patients with hematological malignancies: a neglected issue. <i>Supportive Care in Cancer</i> , 2018, 26, 1699-1701.	1.0	9
98	Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. <i>Annals of Hematology</i> , 2018, 97, 1577-1580.	0.8	32
99	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	0.8	46
100	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with secondâ€”generation tyrosine kinase inhibitors in the realâ€”life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161.	2.0	26
101	Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. <i>Annals of Hematology</i> , 2018, 97, 1357-1367.	0.8	14
102	Ponatinib efficacy and safety in Philadelphia chromosomeâ€”positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , 2018, 132, 393-404.	0.6	392
103	Efficacy and safety of ruxolitinib in intermediateâ€”1 IPSS risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	0.8	29
104	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100.	0.8	32
105	The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 555.	1.3	18
106	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.4	23
107	Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm. <i>Acta Haematologica</i> , 2018, 140, 231-233.	0.7	5
108	Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 623-628.	1.0	10

#	ARTICLE	IF	CITATIONS
109	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. <i>Frontiers in Oncology</i> , 2018, 8, 194.	1.3	84
110	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	1.2	7
111	Chronic myeloproliferative disorders: is quality-of-life the new goal?. <i>Current Medical Research and Opinion</i> , 2018, 34, 1345-1347.	0.9	2
112	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	1.8	24
113	Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up. <i>Blood</i> , 2018, 132, 4255-4255.	0.6	6
114	Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy. <i>Blood</i> , 2018, 132, 4254-4254.	0.6	6
115	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. <i>Blood</i> , 2018, 132, 43-43.	0.6	10
116	International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. a GIMEMA and HOVON Study. <i>Blood</i> , 2018, 132, 1750-1750.	0.6	6
117	Kinetics of BCR-ABL after TKI Interruption during Pregnancy in CML: A Multinational Retrospective Analysis. <i>Blood</i> , 2018, 132, 4263-4263.	0.6	6
118	Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Level. Comparison of Qpcr, d-PCR and CD26 Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR). <i>Blood</i> , 2018, 132, 4244-4244.	0.6	2
119	Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment. <i>Hematological Oncology</i> , 2017, 35, 69-78.	0.8	25
120	The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. <i>American Journal of Hematology</i> , 2017, 92, 797-805.	2.0	71
121	Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocythemia transformation. <i>Acta Oncologica</i> , 2017, 56, 1331-1333.	0.8	7
122	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1530-1536.	1.7	15
123	HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia. <i>Leukemia Research</i> , 2017, 61, 1-5.	0.4	12
124	The DESTINY of chronic myeloid leukaemia. <i>Lancet Haematology</i> , 2017, 4, e303-e304.	2.2	3
125	Advanced chronic myelomonocytic leukemia in elderly and frail patients managed by azacitidine in the field of clinical practice. <i>Annals of Hematology</i> , 2017, 96, 1591-1593.	0.8	3
126	First-line treatment selection and early monitoring patterns in chronic phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. <i>American Journal of Hematology</i> , 2017, 92, 1214-1223.	2.0	36

#	ARTICLE	IF	CITATIONS
127	Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. <i>Annals of Hematology</i> , 2017, 96, 387-391.	0.8	14
128	Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 751-755.	0.9	4
129	Hodgkin's lymphoma in a man with dilated cardiomyopathy and paraneoplastic ataxia: a therapeutical challenge. <i>Hematology Reports</i> , 2017, 9, 6944.	0.3	1
130	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017, 8, 79073-79086.	0.8	63
131	Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2016, 91, 617-622.	2.0	10
132	Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. <i>Journal of Hematology and Oncology</i> , 2016, 9, 63.	6.9	18
133	Primitive "Spindle Cell Variant" (Sarcomatoid Variant) Diffuse Large B-Cell Lymphoma of the Uterine Cervix: Description and Outcome of a Rare Case. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 593-597.	0.9	10
134	Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016, 18, 536-540.	2.3	24
135	Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase. <i>Haematologica</i> , 2016, 101, e267-e268.	1.7	7
136	Management of pregnant chronic myeloid leukemia patients. <i>Expert Review of Hematology</i> , 2016, 9, 781-791.	1.0	55
137	Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. <i>Leukemia</i> , 2016, 30, 1615-1619.	3.3	16
138	Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , 2016, 40, 24-29.	0.4	6
139	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. <i>Blood</i> , 2016, 128, 3070-3070.	0.6	10
140	Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. <i>Oncotarget</i> , 2016, 7, 72311-72321.	0.8	26
141	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	0.8	24
142	The Neutrophil/Lymphocyte Ratio (N/L) Is a Prognostic Marker in Patients with Diffuse Large B Cell Lymphoma: A Prospective Study from the Lazio Lymphoma Registry. <i>Blood</i> , 2016, 128, 3050-3050.	0.6	0
143	Age and d<sc>PCR</sc> can predict relapse in <sc>CML</sc> patients who discontinued imatinib: The <sc>ISAV</sc> study. <i>American Journal of Hematology</i> , 2015, 90, 910-914.	2.0	181
144	The impact of dasatinib on pregnancy outcomes. <i>American Journal of Hematology</i> , 2015, 90, 1111-1115.	2.0	98

#	ARTICLE	IF	CITATIONS
145	Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2015, 7, e2015020.	0.5	12
146	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
147	Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. <i>Blood Cancer Journal</i> , 2015, 5, e347-e347.	2.8	29
148	Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. <i>Leukemia</i> , 2015, 29, 1823-1831.	3.3	77
149	Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. <i>Experimental Hematology</i> , 2015, 43, 1015-1018.e1.	0.2	51
150	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. <i>Leukemia Research</i> , 2015, 39, 1055-1059.	0.4	57
151	Imatinib Suspension and Validation (ISAV) Study: Results at 24 Months. <i>Blood</i> , 2015, 126, 2775-2775.	0.6	3
152	Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial. <i>Blood</i> , 2015, 126, 4025-4025.	0.6	7
153	Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study. <i>Blood</i> , 2015, 126, 5142-5142.	0.6	0
154	TYROSINE KINASE INHIBITORS AND PREGNANCY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014028.	0.5	91
155	Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML). <i>BioDrugs</i> , 2014, 28, 17-26.	2.2	24
156	Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. <i>American Journal of Hematology</i> , 2014, 89, 119-124.	2.0	14
157	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014, 38, 1173-1176.	0.4	30
158	Omitting Radiotherapy in Early Positron Emission Tomographyâ€“Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1188-1194.	0.8	349
159	Gimema Registry of Conception/Pregnancy in Adult Patients Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). <i>Blood</i> , 2014, 124, 1806-1806.	0.6	5
160	Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial. <i>Blood</i> , 2014, 124, 3135-3135.	0.6	43
161	Subcutaneous Immunoglobulin (SCIG) in Responders to Intravenous Therapy with Chronic Immune Thrombocytopenia (ITP). <i>Blood</i> , 2014, 124, 5012-5012.	0.6	2
162	The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis. <i>Blood</i> , 2014, 124, 813-813.	0.6	4

#	ARTICLE	IF	CITATIONS
163	Effectiveness and Safety of Low Dose Eltrombopag Twice Weekly in ITP Patients That Achieved CR after 50mg Daily Standard Dose. <i>Blood</i> , 2014, 124, 2788-2788.	0.6	0
164	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. <i>Drugs and Aging</i> , 2013, 30, 629-637.	1.3	36
165	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. <i>Annals of Hematology</i> , 2013, 92, 179-183.	0.8	12
166	A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias. <i>New England Journal of Medicine</i> , 2013, 369, 1783-1796.	13.9	944
167	Primary pulmonary Hodgkin Lymphoma simulating a mediastinal tumour: an uncommon occurrence.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013013.	0.5	3
168	Dysgeusia in patients with hematological malignancies: a reminder for hematologist. <i>Journal of Oral Pathology and Medicine</i> , 2013, 42, 352-353.	1.4	0
169	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. <i>Blood</i> , 2013, 121, 5138-5144.	0.6	49
170	Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. <i>Haematologica</i> , 2013, 98, 399-403.	1.7	42
171	Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). <i>Blood</i> , 2013, 122, 1496-1496.	0.6	4
172	Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. <i>Blood</i> , 2013, 122, 1498-1498.	0.6	8
173	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. <i>Blood</i> , 2013, 122, 258-258.	0.6	2
174	Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial. <i>Blood</i> , 2013, 122, 2738-2738.	0.6	2
175	Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML). <i>Blood</i> , 2013, 122, 4007-4007.	0.6	6
176	Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial. <i>Blood</i> , 2013, 122, 650-650.	0.6	8
177	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. <i>Blood</i> , 2013, 122, 1486-1486.	0.6	0
178	Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment. <i>Mechanisms of Ageing and Development</i> , 2012, 133, 479-488.	2.2	9
179	Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2012, 120, 761-767.	0.6	110
180	Evaluation of residual CD34 ⁺ Ph ⁺ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. <i>Cancer</i> , 2012, 118, 5265-5269.	2.0	13

#	ARTICLE	IF	CITATIONS
181	Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. <i>Blood</i> , 2012, 120, 3747-3747.	0.6	6
182	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. <i>Haematologica</i> , 2011, 96, 1457-1461.	1.7	58
183	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. <i>Leukemia Research</i> , 2011, 35, 1164-1169.	0.4	28
184	Tattoo related pyoderma/ectyema gangrenous as presenting feature of relapsed acute myeloid leukaemia: An exceptionally rare observation. <i>Injury</i> , 2011, 42, 546-547.	0.7	17
185	Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. <i>Experimental Hematology</i> , 2011, 39, 653-665.e6.	0.2	37
186	Severe Peripheral Arterial Disease During Nilotinib Therapy. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1347-1348.	3.0	145
187	Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2011, 86, 523-525.	2.0	7
188	Reversible hair depigmentation in a patient treated with imatinib. <i>Leukemia Research</i> , 2011, 35, e64-e66.	0.4	19
189	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 553-561.	3.0	362
190	Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. <i>Cancer</i> , 2010, 116, 5667-5675.	2.0	14
191	Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients. <i>Cancer Science</i> , 2010, 101, 991-1000.	1.7	6
192	Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 2748-2754.	0.8	56
193	Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.. <i>Blood</i> , 2010, 116, 3413-3413.	0.6	2
194	Abstract 2143: High-Resolution Molecular Karyotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Identifies Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes. , 2010, , .		1
195	Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 2270-2270.	0.6	0
196	Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party. <i>Blood</i> , 2010, 116, 2279-2279.	0.6	0
197	Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs.. <i>Blood</i> , 2010, 116, 3409-3409.	0.6	2
198	Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. <i>Blood</i> , 2010, 116, 2281-2281.	0.6	0

#	ARTICLE	IF	CITATIONS
199	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. Blood, 2010, 116, 1230-1230.	0.6	2
200	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients â€œ EudraCT Number 2007â€œ005102-42, ClinicalTrials.Gov NCT 00858806.. Blood, 2010, 116, 3412-3412.	0.6	0
201	Imatinib In Very Elderly CML Patients: What Can We Achieve?.. Blood, 2010, 116, 1229-1229.	0.6	0
202	Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.. Blood, 2010, 116, 3375-3375.	0.6	2
203	Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. Journal of Clinical Oncology, 2009, 27, 3472-3479.	0.8	181
204	Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response. Clinical Cancer Research, 2009, 15, 1059-1063.	3.2	28
205	Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood, 2009, 113, 4497-4504.	0.6	173
206	Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood, 2009, 114, 2168-2171.	0.6	160
207	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood, 2009, 114, 4939-4943.	0.6	62
208	High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.. Blood, 2009, 114, 2176-2176.	0.6	1
209	Peptide-Vaccine Treatment Associated with TKI Therapy in Patients with CML Is Able to Induce Immunologic, Cytogenetic and Molecular Responses: a Single Center Experience with Long-Term Follow up.. Blood, 2009, 114, 2185-2185.	0.6	1
210	Chronic Myeloid Leukemia (CML) Patients with â€œSuboptimalâ€œResponse to Imatinib (IM) According to European LeukemiaNet Criteria Have a Poorer Outcome with Respect to â€œOptimalâ€œResponders: A GIMEMA CML WORKING PARTY Analysis.. Blood, 2009, 114, 2196-2196.	0.6	3
211	Prospective Exploratory Phase II Studies of A Rotating Regime of Nilotinib and Imatinib for Frontline Treatment of Philadelphia POSITIVE (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 4972-4972.	0.6	1
212	Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.. Blood, 2009, 114, 2199-2199.	0.6	0
213	Pegylated Liposomal Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (CBVD) in the Treatment of Advanced Primary Cutaneous Lymphomas.. Blood, 2009, 114, 3717-3717.	0.6	1
214	Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.. Blood, 2009, 114, 2211-2211.	0.6	0
215	Late Development of Cytogenetic Abnormalities in Ph Negative Cells of Chronic Myeloid Leukemia Patients Treated with Imatinib.. Blood, 2009, 114, 1108-1108.	0.6	0
216	Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities.. Blood, 2009, 114, 2164-2164.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , 2008, 26, 106-111.	0.8	48
218	153Sm: its use in multiple myeloma and report of a clinical experience. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1379-1387.	1.9	15
219	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. <i>Blood</i> , 2008, 111, 1834-1839.	0.6	284
220	Characterization of Ph-negative abnormal clones emerging during imatinib therapy. <i>Cancer</i> , 2007, 109, 2466-2472.	2.0	29
221	PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells. <i>BMC Cancer</i> , 2007, 7, 207.	1.1	6
222	Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A New Class of Agents with High Apoptotic Activity in Chronic Myelogenous Leukemia K562 Cells and in Cells from Patients at Onset and Who Were Imatinib-Resistant. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5840-5844.	2.9	56
223	Catamenial Bernard-Horner's Syndrome Related to Thoracic Endometriosis. <i>Annals of Thoracic Surgery</i> , 2006, 82, e24-e25.	0.7	4
224	Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825. <i>Blood</i> , 2006, 107, 4571-4572.	0.6	7
225	Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid Leukemia Who Obtained a Complete Cytogenetic Response Within 1 Year of Imatinib Therapy and Those Who Achieved Such a Response After 12 Months of Treatment. <i>Journal of Clinical Oncology</i> , 2006, 24, 454-459.	0.8	42
226	Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2006, 12, 7374-7379.	3.2	475
227	Long Term Follow up on Patients with Ph-Abnormal Clones Emerged during Imatinib Therapy.. <i>Blood</i> , 2006, 108, 2116-2116.	0.6	0
228	Pyrrolo[1,2-B][1,2,5] benzodiazepines (PBTDs) Compounds Induce Apoptosis in Chronic Myeloid Leukaemia Cells from Patients at Onset, Imatinib and Second Generation TK Inhibitors (Dasatinib,) <i>Tj ETQq0 0 0 rgBT, 4 Overlock 10 Tf 50</i>		
229	ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 4100-4109.	0.8	350
230	New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia. <i>Leukemia Research</i> , 2001, 25, 349-351.	0.4	13
231	Monosomy X as a recurring sole cytogenetic abnormality associated with myelodysplastic diseases. <i>Cancer Genetics and Cytogenetics</i> , 1997, 93, 140-146.	1.0	21
232	Study of clonality in myelodysplastic syndromes: Detection of trisomy 8 in bone marrow cell smears by fluorescence in situ hybridization. <i>Leukemia Research</i> , 1996, 20, 551-557.	0.4	16
233	High-dose chemotherapy in adult acute myeloid leukemia: Rationale and results. <i>Leukemia Research</i> , 1996, 20, 535-549.	0.4	14